Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment
RNA chemical modifications are a new but rapidly developing field. They can directly affect RNA splicing, transport, stability, and translation. Consequently, they are involved in the occurrence and development of diseases that have been studied extensively in recent years. However, few studies have...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253122000774 |
| _version_ | 1818060916732723200 |
|---|---|
| author | Ke Liu Qian-Ying Ouyang Yan Zhan Hui Yin Bo-Xuan Liu Li-Ming Tan Rong Liu Wei Wu Ji-Ye Yin |
| author_facet | Ke Liu Qian-Ying Ouyang Yan Zhan Hui Yin Bo-Xuan Liu Li-Ming Tan Rong Liu Wei Wu Ji-Ye Yin |
| author_sort | Ke Liu |
| collection | DOAJ |
| description | RNA chemical modifications are a new but rapidly developing field. They can directly affect RNA splicing, transport, stability, and translation. Consequently, they are involved in the occurrence and development of diseases that have been studied extensively in recent years. However, few studies have focused on the correlation between chemical modifications and drug effects. Here, we provide a landscape of six RNA modifications in pharmacogene RNA (pharmacoepitranscriptomics) to fully clarify the correlation between chemical modifications and drugs. We performed systematic and comprehensive analyses on pharmacoepitranscriptomics, including basic characteristics of RNA modification and modification-associated mutations and drugs affected by them. Our results show that chemical modifications are common in pharmacogenes, especially N6-methyladenosine (m6A) modification. In addition, we found a very close relationship between chemical modifications and anti-tumor drugs. More interestingly, the results demonstrate the importance of m6A modification for anti-tumor drugs, especially for drugs in triple-negative breast cancer (TNBC), ovarian cancer, and acute myelocytic leukemia (AML). These results indicate that pharmacoepitranscriptomics could be a new source of drug-effect biomarkers, especially for m6A and anti-tumor drugs. |
| first_indexed | 2024-12-10T13:40:01Z |
| format | Article |
| id | doaj.art-6a0f24a944ca420991b8b27383147c57 |
| institution | Directory Open Access Journal |
| issn | 2162-2531 |
| language | English |
| last_indexed | 2024-12-10T13:40:01Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj.art-6a0f24a944ca420991b8b27383147c572022-12-22T01:46:42ZengElsevierMolecular Therapy: Nucleic Acids2162-25312022-06-0128464476Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatmentKe Liu0Qian-Ying Ouyang1Yan Zhan2Hui Yin3Bo-Xuan Liu4Li-Ming Tan5Rong Liu6Wei Wu7Ji-Ye Yin8Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, P.R. China; National Clinical Research Center for Geriatric Disorders, Changsha, P.R. ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, P.R. China; National Clinical Research Center for Geriatric Disorders, Changsha, P.R. ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, P.R. China; National Clinical Research Center for Geriatric Disorders, Changsha, P.R. ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, P.R. China; National Clinical Research Center for Geriatric Disorders, Changsha, P.R. ChinaDepartment of Precision Medicine Center, The Second People’s Hospital of Huaihua, Huaihua, P.R. ChinaClinical Pharmacy Center, The Second People’s Hospital of Huaihua, Huaihua, P.R. ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, P.R. China; National Clinical Research Center for Geriatric Disorders, Changsha, P.R. ChinaDepartment of Geriatric Surgery, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha 410008, P.R. China; Corresponding author Wei Wu, Department of Geriatric Surgery, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha 410008, P.R. China.Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, P.R. China; National Clinical Research Center for Geriatric Disorders, Changsha, P.R. China; Hunan Provincial Gynecological Cancer Diagnosis and Treatment Engineering Research Center, Changsha, P.R. China; Corresponding author Ji-Ye Yin, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China.RNA chemical modifications are a new but rapidly developing field. They can directly affect RNA splicing, transport, stability, and translation. Consequently, they are involved in the occurrence and development of diseases that have been studied extensively in recent years. However, few studies have focused on the correlation between chemical modifications and drug effects. Here, we provide a landscape of six RNA modifications in pharmacogene RNA (pharmacoepitranscriptomics) to fully clarify the correlation between chemical modifications and drugs. We performed systematic and comprehensive analyses on pharmacoepitranscriptomics, including basic characteristics of RNA modification and modification-associated mutations and drugs affected by them. Our results show that chemical modifications are common in pharmacogenes, especially N6-methyladenosine (m6A) modification. In addition, we found a very close relationship between chemical modifications and anti-tumor drugs. More interestingly, the results demonstrate the importance of m6A modification for anti-tumor drugs, especially for drugs in triple-negative breast cancer (TNBC), ovarian cancer, and acute myelocytic leukemia (AML). These results indicate that pharmacoepitranscriptomics could be a new source of drug-effect biomarkers, especially for m6A and anti-tumor drugs.http://www.sciencedirect.com/science/article/pii/S2162253122000774MT: bioinformaticspharmacoepitranscriptomicspharmacogenechemical modificationsN6-methyladenosinem6A |
| spellingShingle | Ke Liu Qian-Ying Ouyang Yan Zhan Hui Yin Bo-Xuan Liu Li-Ming Tan Rong Liu Wei Wu Ji-Ye Yin Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment Molecular Therapy: Nucleic Acids MT: bioinformatics pharmacoepitranscriptomics pharmacogene chemical modifications N6-methyladenosine m6A |
| title | Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment |
| title_full | Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment |
| title_fullStr | Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment |
| title_full_unstemmed | Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment |
| title_short | Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment |
| title_sort | pharmacoepitranscriptomic landscape revealing m6a modification could be a drug effect biomarker for cancer treatment |
| topic | MT: bioinformatics pharmacoepitranscriptomics pharmacogene chemical modifications N6-methyladenosine m6A |
| url | http://www.sciencedirect.com/science/article/pii/S2162253122000774 |
| work_keys_str_mv | AT keliu pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT qianyingouyang pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT yanzhan pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT huiyin pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT boxuanliu pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT limingtan pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT rongliu pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT weiwu pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment AT jiyeyin pharmacoepitranscriptomiclandscaperevealingm6amodificationcouldbeadrugeffectbiomarkerforcancertreatment |